SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.44-2.7%11:15 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob L who wrote (7551)12/19/2002 3:05:29 PM
From: Vector1  Read Replies (1) of 52153
 
Bob, no question MDS should be followed. However, MDS is generally associated with both radiation and chemotherapy. Anything that comparomised the marrow. The interesting fact on the MDS incidence in Bex patients it that it only occured in the very long term reponders (over 5 years). All these patients had been through numerous chemo regimes before bex and would have been expected to have higher rates of AML. In addition it is likely that all these patients would not have survived long enough to get AML without Bex. It will be interesting to see the long term data with Zev as well although there has not been much of a record of very long term responders. One would think that Y which tends to settle in the marrow would result in greater incidence of AML but only time and long term studies will tell.

V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News